Lung cancer and risk of cardiovascular mortality
PurposeThe aim of the present study was to investigate the cardiovascular mortality risk among lung cancer patients compared to the general population.MethodsUsing data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we conducted a population-based coho...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1491912/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558755709288448 |
|---|---|
| author | Chengshi Wang Zhu Wang Jing Yang Songbo Zhang Purong Zhang Ye Yang |
| author_facet | Chengshi Wang Zhu Wang Jing Yang Songbo Zhang Purong Zhang Ye Yang |
| author_sort | Chengshi Wang |
| collection | DOAJ |
| description | PurposeThe aim of the present study was to investigate the cardiovascular mortality risk among lung cancer patients compared to the general population.MethodsUsing data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we conducted a population-based cohort study including 278,418 lung cancer patients aged over 30 years between 1 January 1990 and 31 December 2020 as well as the general population. Poisson regression was employed to calculate incidence rate ratios (IRRs) for cardiovascular mortality.ResultsPatients exhibited a significantly higher IRR of cardiovascular mortality risk compared to the general population [IRR 1.74, 95% confidence interval (CI) 1.71–1.77]. The risk was most pronounced in patients aged 30–79 years (IRR 2.61, 95% CI 2.55–2.66), peaking at ages 30–34 years (IRR 48.93, 95% CI 21.98–108.92). Elevated cardiovascular mortality risks were observed across all subgroups, including diseases of the heart (IRR 1.79, 95% CI 1.75–1.82), cerebrovascular diseases (IRR 1.52, 95% CI 1.45–1.59), and other cardiovascular diseases (IRR 1.78, 95% CI 1.67–1.90). The first month after diagnosis presented the highest risk for patients aged 30–79 years (IRR 12.08, 95% CI 11.49–12.70) and ≥80 years (IRR 4.03, 95% CI 3.70–4.39). Clinical characteristics significantly modified cardiovascular mortality.ConclusionsIntegrating cardiovascular disease monitoring and proactive management into lung cancer treatment protocols is essential to the improvement of overall survival and quality of life for lung cancer patients, particularly those who were young or with advanced tumor stage. |
| format | Article |
| id | doaj-art-2c5205dfca074b368ddb7c5cf67cfa97 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-2c5205dfca074b368ddb7c5cf67cfa972025-01-06T06:58:45ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011110.3389/fcvm.2024.14919121491912Lung cancer and risk of cardiovascular mortalityChengshi Wang0Zhu Wang1Jing Yang2Songbo Zhang3Purong Zhang4Ye Yang5Department of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaInstitute for Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Thoracic Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaPurposeThe aim of the present study was to investigate the cardiovascular mortality risk among lung cancer patients compared to the general population.MethodsUsing data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we conducted a population-based cohort study including 278,418 lung cancer patients aged over 30 years between 1 January 1990 and 31 December 2020 as well as the general population. Poisson regression was employed to calculate incidence rate ratios (IRRs) for cardiovascular mortality.ResultsPatients exhibited a significantly higher IRR of cardiovascular mortality risk compared to the general population [IRR 1.74, 95% confidence interval (CI) 1.71–1.77]. The risk was most pronounced in patients aged 30–79 years (IRR 2.61, 95% CI 2.55–2.66), peaking at ages 30–34 years (IRR 48.93, 95% CI 21.98–108.92). Elevated cardiovascular mortality risks were observed across all subgroups, including diseases of the heart (IRR 1.79, 95% CI 1.75–1.82), cerebrovascular diseases (IRR 1.52, 95% CI 1.45–1.59), and other cardiovascular diseases (IRR 1.78, 95% CI 1.67–1.90). The first month after diagnosis presented the highest risk for patients aged 30–79 years (IRR 12.08, 95% CI 11.49–12.70) and ≥80 years (IRR 4.03, 95% CI 3.70–4.39). Clinical characteristics significantly modified cardiovascular mortality.ConclusionsIntegrating cardiovascular disease monitoring and proactive management into lung cancer treatment protocols is essential to the improvement of overall survival and quality of life for lung cancer patients, particularly those who were young or with advanced tumor stage.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1491912/fulllung cancergeneral populationmortalitycardiovascular diseaseincidence rate ratio |
| spellingShingle | Chengshi Wang Zhu Wang Jing Yang Songbo Zhang Purong Zhang Ye Yang Lung cancer and risk of cardiovascular mortality Frontiers in Cardiovascular Medicine lung cancer general population mortality cardiovascular disease incidence rate ratio |
| title | Lung cancer and risk of cardiovascular mortality |
| title_full | Lung cancer and risk of cardiovascular mortality |
| title_fullStr | Lung cancer and risk of cardiovascular mortality |
| title_full_unstemmed | Lung cancer and risk of cardiovascular mortality |
| title_short | Lung cancer and risk of cardiovascular mortality |
| title_sort | lung cancer and risk of cardiovascular mortality |
| topic | lung cancer general population mortality cardiovascular disease incidence rate ratio |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1491912/full |
| work_keys_str_mv | AT chengshiwang lungcancerandriskofcardiovascularmortality AT zhuwang lungcancerandriskofcardiovascularmortality AT jingyang lungcancerandriskofcardiovascularmortality AT songbozhang lungcancerandriskofcardiovascularmortality AT purongzhang lungcancerandriskofcardiovascularmortality AT yeyang lungcancerandriskofcardiovascularmortality |